Healthcare Aug 07, 2020 07:51 PM (GMT+8) · EqualOcean
Hangzhou TigerMed, a tier-one Chinese contract research organization (CRO), today was listed on the Hong Kong Stock Exchange. It has become the third CRO dual-listed on the Hong Kong (03347:HK) and Mainland (300347:SZ) public markets, following WuXi AppTec (603259:SH; 02359:HK) and Pharmaron (300759:SZ;03759:HK). The company issued 107 million shares at HKD 100 at a relatively higher-area of the price range and saw a 19% increase to the opening price of HKD 119. Backed up by the enormous market size and established competition stance, it raised an IPO fund of HKD 10.7 billion this time.
Related companies: